S-707106
Asset
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1,357
- Trials
- 1
- Developer
Indications
1Type 2 diabetes
Phase 2, Completed, NCT01240759, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1,357
- Evidence for its targets1
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.